Effect of perioperative selective alpha-1 blockers in non-stented ureteroscopic laser lithotripsy for ureteric stones: a randomized controlled trial

0 Comments

A.M. Tawfeek(1), M.S. Abdelwahab(2), Ahmed Higazy(1), Ahmed Radwan(1), Sh.A. Swar(2), Hassan Shaker(1), Ahmed Farouk(2)
(1)Ain Shams University Hospitals, Department of Urology, Cairo, Egypt
(2)National Institute of Urology and Nephrology, Cairo, Egypt

Citation:

Tawfeek AM, Abdelwahab MS, Higazy A, et al. Effect of perioperative selective alpha-1 blockers in non-stented ureteroscopic laser lithotripsy for ureteric stones: a randomized controlled trial. Cent European J Urol. 2020; 73: 520-525.

Introduction

The aim of this studywas to assess the efficacy of perioperative alpha-1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.

Material and methods

A randomized control trial was conducted at two high volume urological centers from September 2017 to December 2018. We enrolled 150 patients with lower ureteric stones. They were randomly divided into two groups. Patients in group A, underwent non-stented ureteroscopy using Ho-YAG laser for stone disintegration and received alpha-1 blockers for one week preoperatively and another two weeks postoperatively. Patients in group B, underwent non-stented ureteroscopy and laser and received a placebo.

Results

One hundred and twenty patients were available for analysis at the end of our study. There was no statistically significant difference found between both groups regarding demographic data and stone parameters. The need for intraoperative ureteric dilatation was 32.7% and 51.6% for both groups A and B respectively with a statistically significant difference. The incidence of lower urinary tract symptoms (LUTS) and the need for analgesics were higher in group B with a statistically significant difference.

Conclusions

Administration of perioperative Flo-max seems to not only to significantly decrease the need for intra-operative dilatation and hence operative time, but also leads to a significant decrease in the development of postoperative LUTs, postoperative pain and the need for analgesia and hospital stay.

Key Words:

Ureteroscopic lithotripsy ‹› Non-stented ‹› Alpha-1 blocker‹› Lower urinary tract symptoms ‹› Postoperative pain

INTRODUCTION

Urolithiasis is a worldwide urological morbidity. Lower ureteric stones represent 70% of all ureteric stones; ureteroscopy and laser (URSL) is considered the first surgical choice for such a condition [1]. Sometimes, surgeons face difficulty in introducing the ureteroscope (URS) into the ureteric orifice to reach the stone. In this case, they employ active ureteric dilatation using balloon or Teflon dilators. Kuntz et al. in their review stated that ureteric balloon dilation before endoscopic treatment of stones was associated with a high success rate, fewer complications and may reduce the need for secondary procedures [2]. Mitchell et al. concluded that serial ureteral dilators represent a safe and effective method to promote ureteral access and allow effective stone treatment in single setting [3].

There are three subtypes of alpha- 1 adrenoceptors (ARs) in the ureteric wall: alpha-1A, alpha-1B and alpha-1D. In the proximal ureter, the distribution of ARs was alpha-1D ≥alpha-1B >alpha-1A. In the distal and middle ureters, the distribution of ARs was alpha-1D > alpha-1A > alpha-1B [4]. Flo-max acts on α1A and α1D receptors causing the relaxation of the ureteric wall, which conse-quently increases the urine bolus and intra-ureteral pressure above the stone and lowers intra-ureteral pressure below the stone by decreasing peristalsis in association with the decrease in basal and micturition pressure, even at the bladder neck; thus, it increases the chance of stone expulsion [5, 6, 7] .

Preoperative Flo-max has been evaluated in previous studies to decrease the need for preoperative ureteric dilatation and increase the success rate of surgery. However, its efficacy and duration of intake are not yet clear [4, 5, 8, 9]. We aim through our study to assess the role of Flo-max in non-stented URSL regarding preoperative ureteric dilatation and its impact on postoperative pain and the need for an analgesic. The regimen of perioperative intake of Flo-max rather than just preoperative intake for 3 days makes this study unique. The correlation between Flo-max intake and postoperative pain is another distinctive point of study.

MATERIAL AND METHODS

This randomized controlled clinical trial was conducted on 150 patients with single lower ureteric stones of size ranging between 0.5 and 2 cm. It was conducted at the Urology Departments in Ain Shams University Hospitals and the National Institute of Urology and Nephrology from September 2017 to December 2018. Patients under the age of 18, pregnant women, or those with urinary tract infections (UTI), uncorrected bleeding disorders or coagulopathies, bilateral ureteric stones, single kidney, ureteral stricture, multiple ipsilateral ureteric stones were excluded from our study. Also, any patients who required ureteric stenting were excluded from our study.

Preoperative assessment was done to document the site and size of the stone. An informed consent was obtained from all patients including counseling on treatment options, procedure potential complications and the need for follow-up.Patients were randomized using computer generated simple randomization into study and control groups. Group A (the study group) contained 75 patients who underwent non-stented ureteroscopy using Ho-YAG laser for stone disintegration. These patients received an alpha-1 blocker ‘one tablet Flo-max 0.4 mg per day’ for one week preoperatively, and for another two weeks postoperatively. Group B (the control group) numbered 75 patients and underwent non-stented ureteroscopy using Ho-YAG laser for stone disintegration.

These patients received placebo. All patients were blind to the medication received. Seven surgeons from two centers performed all surgical procedures. Ureteroscopy was performed using a 6.5/9.5 Fr. semi-rigid ureteroscope (Wolf, Richard Wolf Medical Instruments Corporation, Illinois, USA) without dilatation if feasible. In some cases, we needed to use ureteric Teflon dilators up to 10 Fr in size. A 365-microns laser fiber was used to disintegrate the stone using the dusting mechanism (high frequency 25 Hz and low energy 0.5 J) and the popcorn was used for tiny stone fragments. No ureteric stent was fixed at the end of operation. In the case of a  complication (avulsion, perforation, mucosal tear, bleeding, proximal calculus migration and thermal injury), a double J stent was fixed for 2 weeks and the patient was excluded from the study.

Our primary end point was the need for intra-operative ureteric dilatation while other parameters including operative time, residual stones, hospital stay, the presence of postoperative pain according to the Mankoski pain scale, need for analgesics, dysuria, hematuria and fever are considered as a secondary endpoint. Non-contrast computed tomography (CT) was used to evaluate our patients after 1 month regarding any residual stones or backpressure change. Statistical analysis Data were collected and entered to the Statistical Package for Social Science (IBM SPSS) version 23.

The quantitative data were presented as mean, standard deviations and ranges when their distribution was found to be parametric and median with interquartile range (IQR) when their distribution was found to be non-parametric. Qualitative data were presented as numbers and percentages. The comparison between the two independent groups with qualitative data was done by using the Chisquare test and/or Fisher exact test only when the expected count in any  cell was found to be less than 5.

The comparison between two independent groups with quantitative data and parametric distribution was done by using Independent t-test while with non-parametric data were done by using Mann- Whitney test. The confidence interval was set to 95% and the margin of error accepted was set to 5%. So, the p-value was considered significant in accordance with the following: p >0.05: Non-significant. p <0.05: Significant. P <0.01: Highly significant.

RESULTS

From the 200 patients initially recruited for th study, 150 were randomized into 2 groups and only 120 patients were available for final analysis as shown in Figure 1. The mean age in group A and B was 39.17 ±9.96 (22–59) and 37.87 ±10.91 (19–60) respectively (P-value = 0.56) with 44 (36.7%) females and 76 (63.3%) males. Patients with previous endourological surgeries in both groups numbered 44 patients (36.7%) while 76 patients (63.3%) had non-urological operative history.

There was no statistically significant difference was found between group A and group B regarding stone parameters as shown in Table 1. There was a statistically significant increase in the need for dilatation in group B compared to group A with (p-value = 0.03), and also in the operation time in group B compared to group A with p-value = 0.04 as shown in (Table 2).

Regarding postoperative complications as shown in Table 3, patients with lower urinary tract symptoms (frequency, urgency and dysuria) were 14 patients (24.13%) in group A while in group B, they were 27 patients (43.54%) this difference showed a statistically significant difference (P-value = 0.025). Twenty five patients (43.1%) in group A had loin pain that needed pain medications using (Mankoski pain scale), compared to 39 patients (62.9%) in group B, the lower need for analgesics in group A showed a highly statistically significant difference (P-value = 0.030).

No patients needed any further surgical intervention in both groups. Postoperative hematuria was seen in 8 patients in group A compared to 14 patients in group B. Two patients (3.44%) developed fever in group A, compared to 4 patients (6.45%) in group B. There were no statistically significant results (p-value = 0.214 and 0.451 respectively).

Postoperative CT did not detect any residual stone or back pressure changes in both groups. There was a statistically significant difference between group A and group B regarding LUTS and the need for analgesia with p-value = 0.02 and 0.03 respectively while no statistically significant difference was found between the two studied groups regarding hematuria and fever. See (Table 3). The mean hospital stay in hours was 27.05 ±11.63 and 32.58 ±15.26 for group A and group B respectively with a statistically significant increase in the postoperative hospital stay for group B (p-value = 0.027).

DISCUSSION

Since the development of ureteroscope by Hopkins in 1956, it has been considered a cornerstone in the management of ureteric stones [10]. Among the different lithotripsy techniques used nowadays, the most used technique is holmium YAG laser. It improves the outcome of ureteroscopy due to its safety, efficacy, and lower morbidity [11]. There is a controversy surrounding post operative stenting; some authors advocate its use because it may decrease postoperative loin pain and ureteric obstruction resulting from ureteric edema while others do not advice its routine use due to disadvantages associated with it such as dysuria, frequency, hematuria, UTI and encrustations. Therefore, postoperative stenting was reserved for a complicated ureteroscopy [7, 10, 11, 12].

Flo-max acts on α-1a- α-1d receptors in the ureter to relax of the ureter and decrease intraluminal pressure. Also, it acts on nerves and neurotransmitters to decrease bladder contraction and pain. Several studies have established its efficacy as medical expulsive therapy, in addition to decreasing stent related symptoms [9, 13, 14, 15]. In our study, Flo-max reduced the need for ureteric dilatation from 51.6% to 32.7% and that was associated with a decrease in the operative time from 52.9 ±13.16 minutes to 48.19 ±11.72 minutes. Abdelaziz and Kidder's study in 2017 reported a statistically significant decrease in the need for ureteric dilatation during URS following Flo-max. In their study, stone disintegration was performed by pneumatic lithoclast and ureteric stent was routinely fixed which together increased the overall operative time [9]. Additionally, Bhattar et al. in 2017 and Aydin et.al in 2018 both evaluated the preoperative alpha-1 blocker using Silodosin on ureteric dilatation in URS. They found a statistically significant decrease in the need for ureteric dilatation during URS and operative time. These results were confirmed in another study by Mohey et al. in 2018 [8, 16, 17].

On the other hand, in 2017, Sokhal et al. reported that there was not a statistically significant decrease in the need for ureteric dilatation during URS when using pre-URS Flo-max. This may be attributed to the short-term use of pre-operative Flo-max – for 3 days only [17, 18]. In our study, the operative time was reduced by 5 minutes and the hospital stay was reduced by 5 hours in group A using Flo-max compared to group B. Despite that both results were statistically significant, it did not reflect a clinically significant difference in both operative time and hospital stay. Abdelaziz and Kidder's study in 2017 showed no statistically significant difference in hospital stay using days instead of hours [9]. Kaler et al. reported that the usage of 1 week preoperative Flo-max increased the success rate of application of 16-French ureteric access sheath without preoperative ureteral stenting which represent a similar concept for successful ureteric access instead of preoperative ureteric stenting before ureteroscopy for lower ureteric stones [19]. Ahmed et al. also concluded that preoperative Flo-max increased the success rate of ureteroscopy in proximal ureteric stones [20].

Our study demonstrated that the use of peri-operative Flo-max, especially for 2 week postoperatively, reduced postoperative pain in the non-stented group and subsequently the need for pain medications. 43.1% of patients with Flo-max compared to 62.9% of patients with placebo needed analgesics. The use of perioperative Flo-max statistically reduced the number of patients who developed postoperative LUTS from 43.54% of patients to 24.13% of patients with Flo-max. In a study conducted by Zhu and colleagues in 2016, the authors reported that (22/40) 55% of patients in non-stented group were pain-free with the use of post-operative Flo-max and (26/40) 65% of patients in the same group had no postoperative LUTS [21]. In 2014, Ketabchi and Mehrabi studied the effect of preoperative Flo-max for one day in non stented URS on postoperative pain, the need for pain medications and LUTS; they reported that the use of preoperative Flo-max resulted in a significant reduction in the number of patients who developed LUTS and a decrease in the need for pain medications [1].

In our study, the incidence of hematuria in patients was reduced by using Flo-max from 22.58% to 13.79%. Moreover, the incidence of postoperative fever was reduced from 6.45% in the patients receiving placebo compared to 3.44% in the Flo-max group. However, these results regarding fever and hematuria were not statistically significant. We do recommend conducting more studies about larger stones burden or in the upper and mid ureteric stones, to confirm our results and the efficacy of using perioperative alpha-1 blockers.

CONCLUSIONS

Administration of perioperative Flo-max seems to not only significantly decrease the need for intraoperative dilatation and hence operative time, but also leads to a significant decrease in the development of post-operative lower urinary tract symptoms, post-operative pain and the need for analgesia and hospital stay.

Ethical approval and consent to participate

The protocol was approved by the Research Ethics Committee of the Faculty of Medicine of Ain Shams University with approval No. (FMASU MS 100/2018).

Consent for participation

Written consent was obtained from all patients before participation.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interest

No competing interests to declare.

Funding

We received no funding in our study.

Author ’s contribution

A.M. Tawfeek: outline study design, primary surgeon, Data collection, Manuscript writing. M.S. Abdelwahab: Outline study design, Data collection. Ahmed Radwan: Methodology section writing and final revision. Ahmed Higazy (corresponding author): Data collection, Introduction, Discussion writing. Sh. A. Swar: Primary surgeon, Abstract writing, final revision. Hassan S. Shaker: Results and discussion writing and final revision. Ahmed Farouk: Abstract and result writing and final revision.

References

1. Ketabchi AA, Mehrabi S. The effect of Flo-max, an alpha-1 receptor antagonist as a medical expelling agent in success rate of ureteroscopic lithotripsy. Nephrourol Mon. 2014; 6: 1-5.

2. Kuntz NJ, Neisius A, Tsivian M, et al. Balloon Dilation of the Ureter: A Contemporary Review of Outcomes and Complications. J Urol. 2015; 194: 413-417.

3. Mitchell C, Kuebker J, McCormick B, Marien T, Herrell SD, Miller NL. Lubriglide Sequential Ureteral Dilators®: A Safe and Effective Method of Ureteral Dilation. J Endourol. 2017; 31: 573-576.

4. Itoh Y, Okada A, Yasui T, et al. Efficacy of selective α1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol. 2011; 18: 672-674.

5. Basri Cakiroglu, Sinanoglu O, Mahmure Uraz. The Effect of Flo-maxon Pain and Clearance According to Ureteral Stone Location After Shock Wave Lithotripsy. Curr TherRes Clin Exp. 2013; 74: 33-35.

6. Pengfei S, Min J, Jie Y, et al. Use of ureteral stent in extracorporeal shock wave lithotripsy for upper urinary calculi: A systematic review and meta-analysis. J Urol. 2011; 186: 1328-1335.

7. Türk C, Neisius A, Petrik A, Seitz C, Skolarikos A, Thomas K. EAU Guidelines on Urolithiasis. Eur Assoc Urol. 2018; 69: 475-482.

8. Aydın M, Kılınç MF, Yavuz A, Bayar G. Do alpha-1 antagonist medications affect the success of semi-rigid ureteroscopy? A prospective, randomised, single-blind, multicentric study. Urolithiasis. 2018; 46: 567-572.

9. Abdelaziz AS, Kidder AM. Flo-max therapy improved the outcome of ureterorenoscopy for lower ureteral stones: A prospective, randomised, controlled, clinical trial. African J Urol. 2017; 23: 148-153.

10. Geavlete P, Multescu R, Geavlete B. Pushing the boundaries of ureteroscopy: Current status and future perspectives. Nat Rev Urol. 2014; 11: 373-382.

11. John TT, Razdan S. Adjunctive Flo-max Improves Stone Free Rate After Ureteroscopic Lithotripsy of Large Renal and Ureteric Calculi: A Prospective Randomized Study. Urology. 2010; 75: 1040-1042.

12. Wang H, Man L, Li G, Huang G, Liu N, Wang J. Meta-analysis of stenting versus non-stenting for the treatment of ureteral stones. PLoS One. 2017; 12: 1-18.

13. Lee KK, Lee MY, Han DY, Jung HJ, Joo MC. Effects of bladder function by early Flo-max treatment in a spinal cord injury rat model. Ann Rehabil Med. 2014; 38: 433-442.

14. Schmidt S, Miernik A. Alpha-blockers as medical expulsive therapy for ureteral stones. Urologe. 2016; 55: 813-816.
15. Hollingsworth JM, Canales BK, Rogers MAM, et al. Alpha blockers for treatment of ureteric stones: Systematic review and meta-analysis. BMJ. 2016; 355: i6112.

16. Bhattar R, Jain V, Tomar V, Yadav SS. Üreter taşı tedavisinde geniş çaplı üreteroskobun ilerletilmesini kolaylaştırmada silodosin ve tadalafilin güvenlilik ve etkinliği: Bir prospektif randomize çalışma. Turkish J Urol. 2017; 43: 484-489.

17. Mohey A, Gharib TM, Alazaby H, Khalil M, Abou-Taleb A, Noureldin YA. Efficacy of silodosin on the outcome of semi-rigid ureteroscopy for the management of large distal ureteric stones: blinded randomised trial. Arab J Urol. 2018; 16: 422-428.

18. Sokhal A, Sankhwar S, Goel A, Kawaljit S. Does Preoperative Alpha  Blockers Facilitates Ureteroscope Insertion At Vesico Ureteric Junction? An Answer From a Prospective Randomized Study. J Urol. 2017; 4 Suppl: e691 692.

19. Kaler KS, Safiullah S, Lama DJ, et al. Medical impulsive therapy (MIT): the impact of 1 week of preoperative Flo-max on deployment of 16-French ureteral access sheaths without preoperative ureteral stent placement. World J Urol . 2018; 36: 2065-2071.

20. Ahmed AF, Maarouf A, Shalaby E, et al. Semi-rigid ureteroscopy for proximal ureteral stones: Does adjunctive Flo-max therapy increase the chance of success? Urol Int. 2017; 98: 411-417.

21. Zhu J, Liang Y, Chen W, et al. Effect of alpha1-blockers on stentless ureteroscopic lithotripsy. Int Braz J Urol. 2016; 42: 101-106. 

Popular Education Articles

4 STAGES TO PASSING KIDNEY STONES

4 STAGES TO PASSING KIDNEY STONES

The goal of this blog is to provide insight into the process of passing a kidney stone. In particular, we will address what you should expect at each of the four stages along the way. For the newbies, kidney Stones can be one of the most frightening experiences of a person’s life. The pain starts almost immediately out of nowhere and typically generates significant panic for the person experiencing the pain. The pain is so great that it commonly elicits a ride in an ambulance or a middle of the night emergency trip to the ER. Either way, not a ton of fun.

Read Article

What Size Kidney Stone Will Pass?

What Size Kidney Stone Will Pass?

What size kidney stone will pass?!? It's a question that we get asked all the time. In general, stones that are less than 9mm in mean diameter have a chance to pass unassisted. However, as you will learn in this blog, there is a very wide degree of variance in the information you will get from your Healthcare Provider.

Read Article

Net Orders Checkout

Item Price Qty Total
Subtotal $0.00
Shipping
Total

Shipping Address

Shipping Methods